Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
MIRM - Mirum Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$140.20
DETAILS
HIGH:
$165.00
LOW:
$123.00
MEDIAN:
$137.50
CONSENSUS:
$140.20
UPSIDE:
38.95%
Stock News
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company's stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,586 shares of the company's stock, valued at approximately $9,551,000. Deutsche Bank AG owned 0.13% of Mirum Pharmaceuticals at the end
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
Price Targets
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
$137.00
(was $98.51)
UBS
Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird
$123.00
(was $95.91)
Robert W. Baird
Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley
$137.00
(was $105.79)
Morgan Stanley
Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital
$135.00
(was $105.79)
RBC Capital
Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright
$140.00
(was $105.79)
Swayampakula Ramakanth
·
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
$148.00
(was $121.91)
Lisa Walter
·
RBC Capital
Mirum Pharmaceuticals (MIRM) PT Raised to $146 at Citizens After ENDO Data Reveal
$146.00
(was $99.34)
CLSA
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
$150.00
(was $94.00)
Morgan Stanley
Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research
$145.00
(was $95.49)
Wolfe Research
Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital
$142.00
(was $104.83)
Joe Kim
·
RBC Capital
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
$165.00
(was $100.92)
Ryan Deschner
·
Raymond James
Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
$185.00
(was $110.08)
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
$138.00
(was $110.08)
Evercore ISI
Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
$136.00
(was $110.08)
Stifel Nicolaus
Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
$129.00
(was $110.08)
Robert W. Baird
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
$140.00
(was $105.79)
Morgan Stanley
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
$175.00
(was $107.92)
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
$112.00
(was $92.48)
Brian Skorney
·
Robert W. Baird
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
$150.00
(was $93.23)
H.C. Wainwright
Mirum Pharmaceuticals (MIRM) PT Raised to $126 at Evercore ISI
$126.00
(was $89.37)
Gavin Clark-Gartner
·
Evercore ISI